Literature DB >> 7501852

Straight border sign of the liver: spectrum of CT appearances and causes.

Y Itai1, S Murata, Y Kurosaki.   

Abstract

Attenuation differences bordered by straight lines within the liver (the straight border sign) are sometimes seen at computed tomography (CT). This phenomenon, which was demonstrated with unenhanced CT over a dozen years ago, does not represent a hepatic mass and is often associated with vascular compromise. Major causes of the straight border sign include fatty liver, confluent fibrosis, radiation hepatitis, and vascular abnormalities such as tumor thrombus, thromboembolus, compression, and arterioportal shunt. The frequency of this finding increases when intense contrast enhancement is used, especially when contrast material is administered via the superior mesenteric artery (CT during arterial portography) or hepatic artery (CT arteriography). The use of spiral CT is apparently increasing the chances of encountering this sign in daily practice. To correctly interpret the straight border sign, one should consider the distribution (anatomic vs nonanatomic), the attenuation (low vs high), and the use and technique of contrast enhancement.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7501852     DOI: 10.1148/radiographics.15.5.7501852

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  13 in total

1.  CT diagnosis of Fitz-Hugh and Curtis syndrome: value of the arterial phase scan.

Authors:  Seung Ho Joo; Myeong-Jin Kim; Joon Seok Lim; Joo Hee Kim; Ki Whang Kim
Journal:  Korean J Radiol       Date:  2007 Jan-Feb       Impact factor: 3.500

2.  Hypereosinophilic syndrome: CT findings in patients with hepatic lobar or segmental involvement.

Authors:  J H Lim; W J Lee; D H Lee; K J Nam
Journal:  Korean J Radiol       Date:  2000 Apr-Jun       Impact factor: 3.500

Review 3.  Role of external beam radiation therapy in management of hepatocellular carcinoma.

Authors:  Hanish Sharma
Journal:  J Clin Exp Hepatol       Date:  2014-07-19

4.  [Pitfalls in computed tomography for diffuse liver diseases].

Authors:  M Dobritz
Journal:  Radiologe       Date:  2012-08       Impact factor: 0.635

Review 5.  Pathology and images of radiation-induced hepatitis: a review article.

Authors:  Shigeyuki Takamatsu; Kazuto Kozaka; Satoshi Kobayashi; Norihide Yoneda; Kotaro Yoshida; Dai Inoue; Azusa Kitao; Takahiro Ogi; Tetsuya Minami; Wataru Kouda; Tomoyasu Kumano; Nobukazu Fuwa; Osamu Matsui; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2018-03-05       Impact factor: 2.374

6.  Confluent hepatic fibrosis in liver cirrhosis: possible relation with middle hepatic venous drainage.

Authors:  Kumi Ozaki; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Tetsuya Minami
Journal:  Jpn J Radiol       Date:  2013-06-06       Impact factor: 2.374

Review 7.  Hepatic arterioportal shunts: dynamic CT and MR features.

Authors:  Byung Ihn Choi; Kyoung Ho Lee; Joon Koo Han; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2002 Jan-Mar       Impact factor: 3.500

8.  Haemodynamic changes in hepatocellular carcinoma and liver parenchyma under balloon occlusion of the hepatic artery.

Authors:  Fumie Sugihara; Satoru Murata; Tatsuo Ueda; Daisuke Yasui; Hidenori Yamaguchi; Izumi Miki; Chiaki Kawamoto; Eiji Uchida; Shin-Ichiro Kumita
Journal:  Eur Radiol       Date:  2016-09-27       Impact factor: 5.315

9.  An isolate alpha-fetoprotein producing gastric cancer liver metastasis emerged in a patient previously affected by radiation induced liver disease.

Authors:  Vincenzo Cardinale; Gianmaria De Filippis; Alessandro Corsi; Augusto La Penna; Michele Rossi; Carlo Catalano; Paolo Bianco; Adriano De Santis; Domenico Alvaro
Journal:  World J Hepatol       Date:  2013-07-27

Review 10.  Interventional treatment for unresectable hepatocellular carcinoma.

Authors:  Satoru Murata; Takahiko Mine; Fumie Sugihara; Daisuke Yasui; Hidenori Yamaguchi; Tatsuo Ueda; Shiro Onozawa; Shin-ichiro Kumita
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.